Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

Yuankai Shi, Peng Liu, Chuan Jin et al.|The Lancet Haematology|2019

Cited by 248